denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: an independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Bleeding and Clotting, Bleeding disorders, Autoimmune disorders, Drug development, Platelet disorders, Education, Supportive Care, Diseases, Thrombocytopenias, Immune Disorders, Treatment Considerations, Non-Biological therapies, Adverse Events
Hematology Disease Topics & Pathways:
Bleeding and Clotting, Bleeding disorders, Autoimmune disorders, Drug development, Platelet disorders, Education, Supportive Care, Diseases, Thrombocytopenias, Immune Disorders, Treatment Considerations, Non-Biological therapies, Adverse Events
Friday, December 6, 2024: 3:00 PM-6:00 PM
Ballroom 20AB
(San Diego Convention Center)
Chair:
Cindy E Neunert, MD, Columbia University Irving Medical Center
Disclosures:
Neunert: Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees; Argenx: Membership on an entity's Board of Directors or advisory committees; UpToDate: Patents & Royalties.
Speakers:
David J Kuter, MD, DPhil, Massachusetts General Hospital
and
María Eva Mingot-Castellano, MD, Hospital Universitario Virgen del Rocío
Disclosures:
Kuter: Immunovant: Consultancy; Inmagenebio: Consultancy; Ligand: Consultancy; Medscape: Consultancy; Merck Sharp Dohme: Consultancy; New York Blood Center: Consultancy; Peerview: Consultancy; PER: Consultancy; Pfizer: Consultancy; Platelet Disorder Support Association: Consultancy; Regeneron: Consultancy; Seismic: Consultancy; Sobi: Consultancy; Takeda: Consultancy, Research Funding; UCB: Consultancy, Research Funding; Up-To-Date: Consultancy; Verve: Consultancy; AIRx: Consultancy; CRICO: Consultancy; Daiichi Sankyo: Consultancy; Dianthus: Consultancy; Hengrui: Consultancy; Electra Therapeutics: Consultancy; Fuji: Consultancy; Hemopure: Consultancy; Incyte: Consultancy; Cellphire: Consultancy; Chugai: Consultancy; Cellularity: Consultancy; Caremark: Consultancy; Bristol Myers Squibb: Consultancy; Argenx: Consultancy; Apellis: Consultancy; Amgen: Consultancy; Alpine: Consultancy; Alnylam: Consultancy, Research Funding; Alexion: Consultancy; Sanofi: Consultancy, Research Funding; Rigel: Consultancy, Research Funding; Principia: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Hutchmed: Consultancy, Research Funding; Biocryst: Consultancy, Research Funding; Kezar: Consultancy; Kyowa-Kirin: Consultancy; Momenta: Consultancy; Nuvig: Consultancy; Platelet Biogenesis: Consultancy; Protagonist: Consultancy; Zafgen: Consultancy. Mingot-Castellano: Sanofi: Honoraria, Speakers Bureau; Grifols: Honoraria, Speakers Bureau; Amgen: Honoraria, Speakers Bureau; Sobi: Honoraria, Speakers Bureau; Takeda: Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau; Novonordisk: Honoraria, Speakers Bureau.
The management of patients with immune thrombocytopenia (ITP) remains challenging, requiring individualized strategies that incorporate patient preferences with the aim of relieving symptoms and improving wellbeing. Hear a patient's view on the impact of living with ITP and its effect on quality of life, before the expert faculty provide practical insights on current and emerging treatments for chronic ITP and how these may be utilized to improve outcomes for patients, including case-based presentations to review management strategies for different patient profiles. Finally, a panel discussion with all three faculty will focus on shared decision-making and collaboration in the clinic, to give patients with chronic ITP the best possible outcomes. The symposium will include interactivity throughout via audience polling and Q&A sessions.
See more of: Friday Satellite Symposia